iRhythm Technologies $IRTC Shares Sold by Sands Capital Management LLC

Posted by Stanley Muller on Jun 15th, 2026

Sands Capital Management LLC lowered its stake in shares of iRhythm Technologies (NASDAQ:IRTC – Free Report) by 24.0% in the fourth quarter, HoldingsChannel reports. The fund owned 1,699,645 shares of the company’s stock after selling 536,465 shares during the quarter. iRhythm Technologies makes up about 0.9% of Sands Capital Management LLC’s portfolio, making the stock its 29th largest position. Sands Capital Management LLC owned 0.05% of iRhythm Technologies worth $301,585,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of IRTC. Tudor Investment Corp ET AL acquired a new position in shares of iRhythm Technologies during the 3rd quarter valued at about $3,439,800,000. Arrowstreet Capital Limited Partnership increased its stake in shares of iRhythm Technologies by 6,415.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock valued at $93,053,000 after acquiring an additional 532,735 shares during the last quarter. Polar Capital Holdings Plc increased its stake in shares of iRhythm Technologies by 24,782.1% during the 3rd quarter. Polar Capital Holdings Plc now owns 335,908 shares of the company’s stock valued at $57,773,000 after acquiring an additional 334,558 shares during the last quarter. Holocene Advisors LP increased its stake in shares of iRhythm Technologies by 2,023.1% during the 2nd quarter. Holocene Advisors LP now owns 313,094 shares of the company’s stock valued at $48,204,000 after acquiring an additional 298,347 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of iRhythm Technologies by 45.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company’s stock worth $147,251,000 after purchasing an additional 259,800 shares during the period.

Insider Buying and Selling

In related news, Director Abhijit Y. Talwalkar purchased 5,312 shares of iRhythm Technologies stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $10.71 per share, with a total value of $56,891.52. Following the transaction, the director owned 25,611 shares of the company’s stock, valued at approximately $274,293.81. The trade was a 26.17% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on IRTC shares. Robert W. Baird decreased their target price on iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, February 20th. The Goldman Sachs Group decreased their target price on iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Canaccord Genuity Group decreased their target price on iRhythm Technologies from $180.00 to $152.00 and set a “buy” rating for the company in a report on Monday, June 1st. BTIG Research reiterated a “buy” rating and set a $185.00 target price on shares of iRhythm Technologies in a report on Wednesday, June 10th. Finally, Needham & Company LLC boosted their target price on iRhythm Technologies from $254.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $187.38.

Read Our Latest Stock Report on IRTC

iRhythm Technologies Price Performance

Shares of NASDAQ:IRTC opened at $113.65 on Monday. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a 1 year low of $101.75 and a 1 year high of $212.00. The stock has a market capitalization of $3.73 billion, a P/E ratio of -132.15 and a beta of 1.27. The stock has a 50-day simple moving average of $117.07 and a 200-day simple moving average of $141.17.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.21. The firm had revenue of $199.39 million for the quarter, compared to analyst estimates of $194.11 million. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.iRhythm Technologies’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.97) EPS. Equities analysts forecast that iRhythm Technologies will post 0.13 earnings per share for the current year.

About iRhythm Technologies

(Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.